Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs

Executive Summary

Amgen's Prolia appears to be the biggest drug on the list of products incurring price inflation penalties in Part B; many of the others have relatively low sales to Medicare.

You may also be interested in...

Medicare Inflation Penalty Hits 64 Products In First Year

CMS’ latest update to the list of products subject to inflation rebates in the Part B brings the total number of different products that will owe rebates in the first year of the new penalty to 64. The headlines about big savings do not match the reality of very modest liabilities for the affected manufacturers.

Medicare Price Inflation Rebate List Revisions A Sign Of IRA Implementation Overload?

The Centers for Medicare and Medicaid Services has a lot on its plate and is under intense stakeholder scrutiny as it implements the price control provisions of the Inflation Reduction Act. 

Medicare Price Inflation Rebates Levied On 27 Part B Drugs In First Round; Pfizer Tops The List

Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts